tiprankstipranks
Trending News
More News >
Red Light Holland Corp (TSE:TRIP)
:TRIP

Red Light Holland (TRIP) AI Stock Analysis

Compare
59 Followers

Top Page

TS

Red Light Holland

(OTC:TRIP)

45Neutral
Red Light Holland's stock faces significant challenges in profitability and technical indicators, impacting its overall score. However, positive corporate events and strategic partnerships provide hope for future growth. The company's financial stability is underpinned by a strong equity position, though persistent operational inefficiencies and negative cash flows remain key concerns.

Red Light Holland (TRIP) vs. S&P 500 (SPY)

Red Light Holland Business Overview & Revenue Model

Company DescriptionRed Light Holland (TRIP) is a company that specializes in the production, distribution, and sale of premium magic truffles in the Netherlands. Operating within the legal framework of the Dutch market, the company is focused on providing safe, responsible, and accessible psychedelic experiences. Red Light Holland aims to educate the public about the benefits and safe usage of psilocybin, the active compound in magic truffles, while also exploring opportunities in the expanding psychedelic sector.
How the Company Makes MoneyRed Light Holland primarily generates revenue through the sale of its magic truffle products in the Netherlands. The company operates in a legal environment that allows the sale of these products, thus capitalizing on the growing interest in psychedelics for both recreational and potential therapeutic use. They have established retail partnerships and developed a direct-to-consumer sales strategy through online and physical stores. Additionally, Red Light Holland engages in educational and community-building activities to promote responsible use, which helps to grow their customer base and brand loyalty. The company may also explore potential international expansion and partnerships to diversify and increase their revenue streams.

Red Light Holland Financial Statement Overview

Summary
Red Light Holland shows revenue growth but struggles with profitability and cash flow. The strong equity position provides stability, yet persistent net losses and negative cash flows indicate a need for strategic improvements in operational efficiency and profitability.
Income Statement
45
Neutral
Red Light Holland shows a positive revenue growth trajectory, increasing from 2020 to 2024. However, the company struggles with negative net profit margins and EBIT, indicating profitability challenges. The TTM data highlights a gross profit margin of 31.22%, but the net income remains negative, reflecting ongoing operational inefficiencies.
Balance Sheet
55
Neutral
The company maintains a strong equity position with an equity ratio of 83.15% in the TTM period, reflecting financial stability. However, the debt-to-equity ratio is low at 0.10, showing limited leverage but a need for more efficient capital utilization. Return on equity is negative due to consistent net losses, indicating underperformance in generating returns on shareholder investments.
Cash Flow
40
Negative
Free cash flow remains negative, though showing some improvement over the years. The operating cash flow to net income ratio is negative, highlighting challenges in converting income into cash. Despite the pharmaceutical industry’s capital demands, the cash flow situation signals a need for better cash management and operational efficiency.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
2.52M4.75M3.95M2.33M110.96K0.00
Gross Profit
811.13K2.02M1.71M617.68K19.35K0.00
EBIT
-7.43M-6.19M-4.95M-9.51M-4.65M-325.17K
EBITDA
-6.63M-5.26M-4.32M-8.55M-4.61M0.00
Net Income Common Stockholders
-12.41M-7.63M-5.40M-14.37M-1.64M-325.17K
Balance SheetCash, Cash Equivalents and Short-Term Investments
14.37M14.17M18.53M26.62M32.78M1.96M
Total Assets
24.08M24.08M30.14M32.94M36.30M3.97M
Total Debt
811.05K1.72M1.77M1.50M866.50K86.77K
Net Debt
-13.56M-12.46M-16.72M-24.59M-30.32M-1.88M
Total Liabilities
3.82M3.82M3.80M3.78M2.24M5.11M
Stockholders Equity
20.07M20.07M26.06M28.48M34.06M-1.14M
Cash FlowFree Cash Flow
-7.73M-3.92M-6.45M-5.28M-3.63M-238.35K
Operating Cash Flow
-4.79M-3.23M-4.39M-4.88M-3.36M-238.35K
Investing Cash Flow
-2.57M-650.43K-3.17M-582.74K-201.55K-1.80M
Financing Cash Flow
341.15K-206.95K-114.16K451.76K32.78M4.01M

Red Light Holland Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.03
Price Trends
50DMA
0.04
Negative
100DMA
0.04
Negative
200DMA
0.04
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
35.81
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Neutral. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.81 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
TSRVV
49
Neutral
C$8.37M-66.49%-4.84%
48
Neutral
$6.36B1.24-44.94%2.70%18.33%1.47%
45
Neutral
C$14.03M-30.44%13.57%-14.29%
42
Neutral
$1.97M-58.79%51.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:TRIP
Red Light Holland
0.04
-0.02
-41.67%
TSE:CYBN
Cybin
0.14
0.00
0.00%
TSE:RVV
Revive Therapeutics
0.02
0.00
0.00%

Red Light Holland Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Red Light Holland’s Happy Caps Expands into U.S. Market with Safeway Partnership
Positive
Apr 7, 2025

Red Light Holland’s subsidiary, Happy Caps Mushroom Farm, has secured a purchase order with Albertsons Companies for its first U.S. retail launch through Safeway stores in Oregon. This strategic partnership will introduce three varieties of Happy Caps Mushroom Home Grow Kits to 66 Safeway locations, marking a significant expansion into the U.S. market. The collaboration with Trailbridge Farms in Oregon ensures product freshness and improved margins, highlighting the growing demand for innovative mushroom products in the health and wellness sector.

Spark’s Take on TSE:TRIP Stock

According to Spark, TipRanks’ AI Analyst, TSE:TRIP is a Neutral.

Red Light Holland faces major challenges in profitability and cash flow, significantly impacting its financial health. The stock’s current technical indicators suggest bearish momentum, and its valuation is not appealing due to negative earnings. However, recent corporate events, including strategic partnerships and leadership enhancements, offer a glimmer of hope for future growth and operational improvement.

To see Spark’s full report on TSE:TRIP stock, click here.

Executive/Board ChangesBusiness Operations and Strategy
Red Light Holland Strengthens Board with New Appointment
Positive
Mar 19, 2025

Red Light Holland has appointed Michael Galloro to its Board of Directors, enhancing its leadership with his extensive experience in public markets, strategic transactions, and corporate governance. Galloro’s proven success in scaling consumer brands is expected to drive sustainable growth and enhance shareholder value as the company expands its functional mushroom and psilocybin truffle offerings.

Product-Related AnnouncementsBusiness Operations and Strategy
Red Light Holland Expands Partnership with Costco Canada for Mushroom Home Grow Kits
Positive
Mar 13, 2025

Red Light Holland, through its subsidiary Happy Caps Mushroom Farms, has received an Informal Projection Letter from Costco Canada for 20,160 units of its ‘Mega Block’ 2kg Mushroom Home Grow Kits. This development, scheduled for delivery in May 2025, signifies a strengthened partnership with Costco Canada and highlights the growing demand for sustainable home grow kits. The company is also eyeing further expansion in North America, including potential orders with a major U.S. retailer.

Business Operations and StrategyFinancial Disclosures
Red Light Holland Reports Q3 2025 Results, Highlights Strategic Growth
Positive
Feb 26, 2025

Red Light Holland reported its financial results for the third quarter of 2025, highlighting a cash balance of $13.3 million and a revenue of $1.2 million for the quarter. Despite a slight decline in quarterly revenue due to lower wholesale mushroom sales and a returned purchase order from Costco Canada, the company achieved a year-over-year revenue increase of 5.1%. The company also reduced its EBITDA loss, reflecting its commitment to sustainable growth and strategic partnerships. Red Light Holland’s diversified portfolio and upcoming partnerships, including a re-order with Costco Canada and a new purchase order with a major U.S. retailer, position it for continued success in the emerging legal psilocybin market.

Product-Related AnnouncementsRegulatory Filings and Compliance
Red Light Holland’s Happy Caps Secures Health Canada Nod for New Mushroom Gummies
Positive
Feb 4, 2025

Red Light Holland’s subsidiary, Happy Caps, has gained Health Canada’s approval for their Functional Daily mushroom gummies, featuring Shiitake and Lion’s Mane mushrooms. This approval highlights the product’s compliance with safety, effectiveness, and quality standards, potentially enhancing the company’s market position in the health and wellness industry.

Product-Related AnnouncementsBusiness Operations and Strategy
Red Light Holland Partners with Irvine Labs to Boost Psilocybin Product Shelf Life for Global Market Expansion
Positive
Jan 30, 2025

Red Light Holland has announced a new research and development plan in collaboration with Irvine Labs Inc., a DEA-registered and FDA-compliant facility. This partnership aims to enhance the shelf life of psilocybin products, which will facilitate commercialization in emerging legal markets. By leveraging proprietary dehydration and packaging techniques, the company intends to meet the growing demand for innovative mental health solutions. The move is expected to position Red Light Holland strategically within the global market for naturally derived therapeutic products.

Executive/Board ChangesBusiness Operations and Strategy
Red Light Holland Appoints New CFO, Eyes Expansion in Psilocybin Market
Positive
Jan 22, 2025

Red Light Holland has appointed Keith Li as the new Chief Financial Officer, bringing over 15 years of experience in corporate accounting and financial strategy to the company. This leadership change is part of the company’s focus on advancing psilocybin access in emerging markets, supported by strong financial leadership. The company is also enthusiastic about its partnership with Irvine Labs, which could enable significant R&D and commercialization opportunities for psilocybin. The appointment of Li is expected to enhance financial efficiencies, support revenue expansion, and strengthen Red Light Holland’s position in the transformative natural plant and fungi medicines industry.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.